Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial

被引：0

作者：

Piccini, Jonathan P. ^{[1
]}

Garg, Jyotsna ^{[2
]}

Patel, Manesh R. ^{[1
]}

Lokhnygina, Yuliya ^{[3
]}

Goodman, Shaun G. ^{[4
,5
]}

Becker, Richard C. ^{[1
]}

Berkowitz, Scott D. ^{[6
]}

Breithardt, Gunter ^{[7
]}

Hacke, Werner ^{[8
]}

Halperin, Jonathan L. ^{[9
]}

Hankey, Graeme I. ^{[10
,11
]}

Nessel, Christopher C. ^{[12
]}

Mahaffey, Kenneth W. ^{[1
]}

Singer, Daniel E. ^{[13
,14
]}

Califf, Robert M. ^{[15
]}

Fox, Keith A. ^{[16
,17
]}

机构：

[1] Duke Clin Rsch Inst, Dept Med, Div Cardiol, Durham, NC USA

[2] Duke Clin Rsch Inst, Stat Grp, Durham, NC USA

[3] Duke Clin Rsch Inst, Dept Biostat & Bioinformat, Durham, NC USA

[4] Univ Toronto, St Michaels Hosp, Canadian Heart Rsch Cntr, Toronto, ON, Canada

[5] Terrence Donnelly Heart Cntr, Toronto, ON, Canada

[6] Bayer HealthCare Pharmaceut, Global Therapeut Rsch, Cardiovasc Pharmacol, Montville, NJ USA

[7] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany

[8] Heidelberg Univ, Dept Neurol, Heidelberg, Germany

[9] Mt Sinai, Icahn Sch Med, Mt Sinai Med Cntr, Cardiovasc Inst, New York, NY USA

[10] Univ Western Australia, Sch Med & Pharmacol, Dept Neurol, Perth, WA 6009, Australia

[11] Royal Perth Hosp, Stroke Unit, Perth, WA 6001, Australia

[12] Janssen Rsch & Dev, Clin Rsch, Raritan, NJ USA

[13] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[14] Harvard Univ, Sch Med, Boston, MA USA

[15] Duke Translat Med Inst, Dept Med, Div Cardiol, Durham, NC USA

[16] Univ Edinburgh, Cntr Cardiovasc Sci, Edinburgh, Midlothian, Scotland

[17] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland

来源：

CIRCULATION | 2013年 / 128卷 / 22期

关键词：

Atrial fibrillation; Stroke; Risk factors;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

15879

引用

页数：2

共 50 条

[31] Frequency and Management of Major Bleeding in Atrial Fibrillation Patients Treated With Warfarin and Non-vitamin K Oral Anticoagulants in Community Practice: Results From the ORBIT-AF II Registry
Steinberg, Benjamin A.
Simon, DaJuanicia N.
Thomas, Laine
Ansel, Jack
Fonarow, Gregg C.
Gersh, Bernard J.
Kowey, Peter R.
Mahaffey, Kenneth W.
Peterson, Eric D.
Piccini, Jonathan P.
CIRCULATION, 2015, 132
[32] Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial
Semco, Robert S.
Bergmark, Regan W.
Murphy, Sabina A.
Cange, Abby L.
Unverdorben, Martin
Chen, Cathy Z. L.
Ruff, Christian T.
Antman, Elliott M.
Giugliano, Robert P.
Bergmark, Brian A.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (02):
[33] Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation: Results from ROCKET AF
Girgis, I. G.
Patel, M. R.
Peters, G. R.
Moore, K. T.
Mahaffey, K. W.
Nessel, C. C.
Halperin, J. L.
Califf, R. M.
Fox, K. A. A.
Becker, R. C.
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (08) : 917 - 927
[34] Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
Quinn, Gene R.
Hellkamp, Anne S.
Hankey, Graeme J.
Becker, Richard C.
Berkowitz, Scott D.
Breithardt, Guenter
Fava, Maurizio
Fox, Keith A. A.
Halperin, Jonathan L.
Mahaffey, Kenneth W.
Nessel, Christopher C.
Patel, Manesh R.
Piccini, Jonathan P.
Singer, Daniel E.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (15):
[35] Rivaroxaban versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial
Berwanger, Otavio
Lopes, Renato D., Sr.
De Barros e Silva, Pedro Gabriel G.
Penna Guimaraes, Helio P.
Kojima, Flavia C.
Bezerra Campos, Viviane B.
Nakagawa, Renato H.
Damiani, Lucas Petri
Paisani, Denise
Santucci, Eliana
Valeis, Nanci
Laranjeira, Ligia N.
Pavanello, Ricardo
Cavalcanti, Alexandre
CIRCULATION, 2020, 142 (24) : E486 - E486
[36] Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF
Van Diepen, Sean
Hellkamp, Anne S.
Patel, Manesh R.
Becker, Richard C.
Breithardt, Gunter
Halperin, Jonathan L.
Hankey, Graeme J.
Nessel, Christopher C.
Singer, Daniel E.
Berkowitz, Scott D.
Califf, Robert M.
Fox, Keith A.
Mahaffey, Kenneth W.
CIRCULATION, 2012, 126 (21)
[37] Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists
Di Nisio, Marcello
Ageno, Walter
Rutjes, Anne W. S.
Pap, Akos F.
Bueller, Harry R.
THROMBOSIS AND HAEMOSTASIS, 2016, 115 (02) : 424 - 432
[38] Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin
Burgess, S.
Crown, N.
Louzada, M. L.
Dresser, G.
Kim, R. B.
Lazo-Langner, A.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (09) : 1647 - 1654
[39] Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
Brambatti, Michela
Darius, Harald
Oldgren, Jonas
Clemens, Andreas
Noack, Herbert H.
Brueckmann, Martina
Yusuf, Salim
Wallentin, Lars
Ezekowitz, Michael D.
Connolly, Stuart J.
Healey, Jeff S.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 196 : 127 - 131
[40] Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Patel, Manesh R.
Hellkamp, Anne S.
Lokhnygina, Yuliya
Piccini, Jonathan P.
Zhang, Zhongxin
Mohanty, Surya
Singer, Daniel E.
Hacke, Werner
Breithardt, Guenter
Halperin, Jonathan L.
Hankey, Graeme J.
Becker, Richard C.
Nessel, Christopher C.
Berkowitz, Scott D.
Califf, Robert M.
Fox, Keith A. A.
Mahaffey, Kenneth W.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (06) : 651 - 658

← 1 2 3 4 5 →